CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS
Ramos, M., Foos, V., Ustyugova, A.V., Hau, N., Gandhi, P., Lamotte, M.Volume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.013
Date:
October, 2018
File:
PDF, 715 KB
english, 2018